Jefferies Upgrades Alto Neuroscience to "Buy"

Font: Financial Modeling Prep  • Mar 16, 2026

• Jefferies has upgraded Alto Neuroscience (NYSE: ANRO) to a "Buy" recommendation, with the stock currently priced at $24.80.
• Alto Neuroscience secures approximately $120 million through private placement financing, aiming to advance its pipeline of precision medicines for neuropsychiatric disorders.
• The stock price of ANRO has seen a significant increase of 11.41%, indicating positive market sentiment following the financing announcement and Jefferies' upgrade.

On March 16, 2026, Jefferies updated its rating for Alto Neuroscience (NYSE: ANRO) to a "Buy" recommendation. At the time of this announcement, the stock was priced at $24.80. Alto Neuroscience is a clinical-stage biopharmaceutical company that focuses on developing precision medicines for neuropsychiatric disorders. This sector is competitive, with companies striving to innovate treatments for mental health conditions.

Alto Neuroscience recently achieved a significant financial milestone by securing approximately $120 million through a private placement financing. This agreement with institutional and accredited investors is expected to support the company's efforts in advancing its pipeline of precision medicines. Such financial backing is crucial for clinical-stage companies like Alto, as it enables them to continue research and development activities.

The stock for ANRO is currently priced at $24.80, reflecting an increase of $2.54, or 11.41%. This rise in stock price indicates positive market sentiment following the financing announcement and Jefferies' "Buy" recommendation. The stock has fluctuated between a low of $21.76 and a high of $24.94 today, with $24.94 marking its highest price over the past year.

Alto Neuroscience's market capitalization stands at approximately $770.45 million, highlighting its presence in the biopharmaceutical industry. The trading volume of 443,423 shares suggests active investor interest. The company's stock has seen significant growth, with its lowest price in the past year being $1.60, showcasing its potential for substantial returns.